难治性特发性血小板减少性紫癜的治疗进展(5)
[15]Burzynski J.New options after first-line therapy for chronic immune thrombocytopenic purpura[J].American Journal of Health-System Pharmacy，2009，66(2)：11-21.
[16]Jun Seok Yoon，Yoo Jin Lee，Dong Won Baek，et al.New synergistic efficacy of combination of romiplostim and steroid in refractory immune thrombocytopenia patients[J].Korean J Intern Med，2016，36(8)：252-254.
[17]Miyakawa Y，Katsutani S，Yano T，et al.Efficacy and safety of rituximab in Japanese patients with relapsed chronic immune thrombocytopenia refractory to conventional therapy[J].International Journal of Hematology，2015，102(6)：654-661.
, 百拇医药
[18]Hammond WA，Rodriguez EM，Li Z，et al.Splenectomy or Rituximab in Steroid-Refractory Immune Thrombocytopenia(ITP)：The Mayo Clinic Experience[J].Blood，2016(128)：3735.
[19]Song I，Kim J，Kwon K，et al.Expression of CD154(CD40L) on stimulated T lymphocytes in patients with idopathic thrombocytopenic purpura[J].Hematology，2016，3(21)：187-192.
[20]Patel VL，Schwartz J，Bussel JB.The effect of anti-CD40 ligand in immune thrombocytopenic purpura[J].Br J Haematol，2010，141(4)：545-548.
, 百拇医药
[21]Liebman HA，Saleh MN，Bussel JB，et al.Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia[J].Hematology，2016，101(11)：1327-1332.
[22]Robak T，Windyga J，Thhnski J，et al.Rozmlimupab，a mixture of 25 recombinant human monoclonal RhD antibodies，in the treatment of primary immune thrombocytopenia[J].Blood，2012，120(18)：3670-3676.
[23]Konstaninova TS，Leonidovna IV，Hellmann A，et al.Interim results from a PhaseⅠbⅡa clinical trial with the soluble Fc-gamma Ⅱb receptor SM101 for the treatment of primary immune thrombocytopenia[J].Polski Tygodnik Lekarski，2012，23(25)：950-953.
, http://www.100md.com
[24]Podolanczuk A，Lazarus AH，Crow AR，et al.Of mice and men：an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk[J].Blood，2009，113(14)：3154-3160.
[25]Bussel JB，Kuter DJ，Aledort LM，et al.A randomized trial of avatrombopag，an investigational thrombopoietin-receptor agonist，in persistent and chronic immune thrombocytopenia[J].Blood，2014，123(25)：3887-3894.
[26]Poudyal BS，Sapkota B，Shrestha GS，et al.Safety and Efficacy of Azathioprine as a Second Line Therapy for Primary Immune Thrombocytopenic Purpura[J].Journal of Nepal Medical Association，2016，55(203)：16-21.
[27]Choi PY，Roncolato F，Badoux X，et al.A novel triple therapy for ITP using high-dose dexamethasone，low-dose rituximab， and cyclosporine(TT4)[J].Blood，2015，126(4)：500-503., 百拇医药(唐培渊 宋俊峰 秦克乐 王寻 阎雄)
[16]Jun Seok Yoon，Yoo Jin Lee，Dong Won Baek，et al.New synergistic efficacy of combination of romiplostim and steroid in refractory immune thrombocytopenia patients[J].Korean J Intern Med，2016，36(8)：252-254.
[17]Miyakawa Y，Katsutani S，Yano T，et al.Efficacy and safety of rituximab in Japanese patients with relapsed chronic immune thrombocytopenia refractory to conventional therapy[J].International Journal of Hematology，2015，102(6)：654-661.
, 百拇医药
[18]Hammond WA，Rodriguez EM，Li Z，et al.Splenectomy or Rituximab in Steroid-Refractory Immune Thrombocytopenia(ITP)：The Mayo Clinic Experience[J].Blood，2016(128)：3735.
[19]Song I，Kim J，Kwon K，et al.Expression of CD154(CD40L) on stimulated T lymphocytes in patients with idopathic thrombocytopenic purpura[J].Hematology，2016，3(21)：187-192.
[20]Patel VL，Schwartz J，Bussel JB.The effect of anti-CD40 ligand in immune thrombocytopenic purpura[J].Br J Haematol，2010，141(4)：545-548.
, 百拇医药
[21]Liebman HA，Saleh MN，Bussel JB，et al.Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia[J].Hematology，2016，101(11)：1327-1332.
[22]Robak T，Windyga J，Thhnski J，et al.Rozmlimupab，a mixture of 25 recombinant human monoclonal RhD antibodies，in the treatment of primary immune thrombocytopenia[J].Blood，2012，120(18)：3670-3676.
[23]Konstaninova TS，Leonidovna IV，Hellmann A，et al.Interim results from a PhaseⅠbⅡa clinical trial with the soluble Fc-gamma Ⅱb receptor SM101 for the treatment of primary immune thrombocytopenia[J].Polski Tygodnik Lekarski，2012，23(25)：950-953.
, http://www.100md.com
[24]Podolanczuk A，Lazarus AH，Crow AR，et al.Of mice and men：an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk[J].Blood，2009，113(14)：3154-3160.
[25]Bussel JB，Kuter DJ，Aledort LM，et al.A randomized trial of avatrombopag，an investigational thrombopoietin-receptor agonist，in persistent and chronic immune thrombocytopenia[J].Blood，2014，123(25)：3887-3894.
[26]Poudyal BS，Sapkota B，Shrestha GS，et al.Safety and Efficacy of Azathioprine as a Second Line Therapy for Primary Immune Thrombocytopenic Purpura[J].Journal of Nepal Medical Association，2016，55(203)：16-21.
[27]Choi PY，Roncolato F，Badoux X，et al.A novel triple therapy for ITP using high-dose dexamethasone，low-dose rituximab， and cyclosporine(TT4)[J].Blood，2015，126(4)：500-503., 百拇医药(唐培渊 宋俊峰 秦克乐 王寻 阎雄)